Vaccine developers pursuing purer subunit vaccines to reduce reactogenicity, often run into problems of poor vaccine immunogenicity. This has driven a resurgence of interest in newer adjuvants. Alu...
No takes yet. Share an insight, caveat, or question.
Nikolai Petrovsky (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: